Stockscreener 앱 받기
5.05
9.82%
-0.55
시간 외 거래:
5.04
-0.010
-0.20%
전일 마감가:
$5.60
열려 있는:
$5.6
하루 거래량:
173.76K
Relative Volume:
0.93
시가총액:
$32.41M
수익:
$7.97M
순이익/손실:
$-75.74M
주가수익비율:
-0.2079
EPS:
-24.2853
순현금흐름:
$-85.33M
1주 성능:
-4.72%
1개월 성능:
-15.13%
6개월 성능:
-48.63%
1년 성능:
-75.06%
1일 변동 폭
$4.9005
$5.71
1주일 범위
$4.77
$6.35
52주 변동 폭
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.05 | 32.41M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Aligos Therapeutics secures $105 million in private placement - MSN
Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stake Lessened by Renaissance Technologies LLC - Defense World
Aligos Therapeutics (ALGS) Gains Buy Rating with Promising Outlo - GuruFocus
Aligos Therapeutics (ALGS) Coverage Initiated with Positive Outl - GuruFocus
Wells Fargo & Company MN Invests $869,000 in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Geode Capital Management LLC Buys 3,197 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Aligos Therapeutics Q1 2025 Earnings: Clinical Stage Biotech Reports Pre-Market May 6Key Focus Areas - Stock Titan
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 - The Manila Times
When the Price of (ALGS) Talks, People Listen - news.stocktradersdaily.com
ALGS stock touches 52-week low at $4.21 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $4.21 amid market challenges - Investing.com India
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN
(ALGS) Investment Analysis - news.stocktradersdaily.com
ALGS stock touches 52-week low at $6.71 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $6.71 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Buys 2,306 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Receives “Buy” Rating from HC Wainwright - Defense World
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Aligos Therapeutics Inc Files For Offering Of Up To 6.2 Million Common Shares By The Selling SecurityholdersSEC Filing - TradingView
(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com
Aligos Therapeutics Presents Positive Data at APASL 2025 - The Manila Times
Clinical Trial Success: Aligos' Dual Breakthroughs in Liver Disease Show 100% Efficacy - Stock Titan
Ten option delistings on March 24th - TipRanks
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
ALG-097558 confirmed as an effective pan-coronavirus strategy - BioWorld MedTech
Learn to Evaluate (ALGS) using the Charts - news.stocktradersdaily.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
HC Wainwright Issues Negative Outlook for ALGS Earnings - Defense World
Financial Comparison: Achilles Therapeutics (NASDAQ:ACHL) vs. Aligos Therapeutics (NASDAQ:ALGS) - Defense World
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy - Investing.com India
Aligos Therapeutics (NASDAQ:ALGS) Price Target Lowered to $70.00 at HC Wainwright - Defense World
Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition - TipRanks
Aligos Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Aligos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aligos Therapeutics reports fourth-quarter and full-year 2024 results -March 10, 2025 at 10:48 am EDT - Marketscreener.com
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last year - TipRanks
Aligos Therapeutics, Inc. SEC 10-K Report - TradingView
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Aligos Q4 Earnings: $105M Raise Backs Promising HBV Drug Results - StockTitan
Earnings Scheduled For March 10, 2025 - Benzinga
Aligos Therapeutics (ALGS) to Release Earnings on Monday - The AM Reporter
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday - Defense World
ALIGOS THERAPEUTICS Earnings Preview: Recent $ALGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
How the (ALGS) price action is used to our Advantage - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short Interest - The AM Reporter
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 23.7% in February - Defense World
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 - The Manila Times
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):